Regeneron Pharmaceuticals Stock Price


0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 0
Bid Price 736.80
Ask Price 744.30
News (1)
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 742.30 19:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 538.01 - 779.00
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 742.30 USD


Draw Mode:

Regeneron Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 80.84B 108.90M 102.47M $ 16.07B $ 5.76B 72.07 15.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -44.79k 2.10%

more financials information »

Regeneron Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical REGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week723.16745.60713.471730.86553,04219.142.65%
1 Month721.16747.70668.00716.46613,78621.142.93%
3 Months725.18779.00668.00733.58629,35817.122.36%
6 Months581.41779.00563.82703.95690,613160.8927.67%
1 Year605.55779.00538.01671.77686,076136.7522.58%
3 Years341.20779.00328.125578.16868,814401.10117.56%
5 Years373.50779.00271.37492.63829,243368.8098.74%

Regeneron Pharmaceuticals Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).